Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Interim Analysis of Long-Term Data with ONGLYZA (saxagliptin) When Added to Metformin in People with Inadequately Controlled Type 2 Diabetes Presented at ADA Annual Scientific Sessions
Interim Analysis of Long-Term Data with ONGLYZA (saxagliptin) When Added to Metformin in People with Inadequately Controlled Type 2 Diabetes Presented at ADA Annual Scientific Sessions
Interim Analysis of Long-Term Data with ONGLYZA (saxagliptin) When Added to Metformin in People with Inadequately Controlled Type 2 Diabetes Presented at ADA Annual Scientific Sessions
Submitted by
admin
on June 7, 2009 - 8:55am
Source:
Yahoo/Business Wire
News Tags:
Bristol-Myers Squibb
AstraZeneca
Onglyza
diabetes
Headline:
Interim Analysis of Long-Term Data with ONGLYZA (saxagliptin) When Added to Metformin in People with Inadequately Controlled Type 2 Diabetes Presented at ADA Annual Scientific Sessions
Do Not Allow Advertisers to Use My Personal information
